Chimerix (NASDAQ:CMRX) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Chimerix (NASDAQ:CMRX) from a sell rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Other research analysts also recently issued reports about the company. ValuEngine upgraded Chimerix from a sell rating to a hold rating in a research report on Thursday, August 1st. HC Wainwright increased their target price on Chimerix from $5.00 to $7.00 and gave the company a buy rating in a research report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $4.00.

Shares of CMRX opened at $2.44 on Tuesday. Chimerix has a 1 year low of $1.74 and a 1 year high of $4.40. The company has a 50 day simple moving average of $2.46 and a two-hundred day simple moving average of $2.88. The firm has a market cap of $145.82 million, a P/E ratio of -1.71 and a beta of 1.34.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.18). Chimerix had a negative net margin of 729.02% and a negative return on equity of 38.70%. The company had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.30 million. As a group, equities research analysts expect that Chimerix will post -1.1 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of CMRX. SG Americas Securities LLC boosted its position in shares of Chimerix by 105.4% during the 1st quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 10,567 shares during the last quarter. Quantitative Systematic Strategies LLC bought a new position in shares of Chimerix during the 2nd quarter valued at approximately $67,000. Susquehanna International Group LLP bought a new position in shares of Chimerix during the 2nd quarter valued at approximately $92,000. Prudential Financial Inc. bought a new position in shares of Chimerix during the 2nd quarter valued at approximately $104,000. Finally, Marshall Wace LLP bought a new position in shares of Chimerix during the 1st quarter valued at approximately $166,000. Hedge funds and other institutional investors own 61.96% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Featured Article: Stocks Increasing Dividends

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit